Thermo Fisher Scientific increases availability of COVID-19 testing with sample collection kit from Everlywell

October 19, 2020  –  Thermo Fisher Scientific Inc. (Waltham, MA) received an expansion of its Emergency Use Authorization (EUA) for the TaqPath COVID-19 Combo Kit to include an additional sample collection method provided by Everlywell, a digital health testing company.

The TaqPath test is authorized for use with the Everlywell COVID-19 Test Home Collection Kit, which enables individuals to self-collect nasal swab specimens when determined by a healthcare provider to be appropriate based on results of a COVID-19 questionnaire.

Samples collected using the Everlywell self-collection kit may be processed by CLIA-certified laboratories running Thermo Fisher’s TaqMan SARS-CoV-2 RNase P Assay Kit, and the results obtained through the Everlywell online platform.

“As part of our commitment to keep our workplaces safe and healthy, Thermo Fisher launched its own pilot program to provide at-home collection kits and online access to test results for more than 10,000 colleagues across the country,” said Mark Stevenson, EVP and COO at Thermo Fisher Scientific.

Learn More